Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov;66(11):941-952.
doi: 10.1111/myc.13637. Epub 2023 Aug 7.

Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: A meta-analysis of 21 studies and 5174 patients

Zia Hashim  1 , Alok Nath  1 , Ajmal Khan  1 , Mansi Gupta  1 , Anup Kumar  2 , Riksoam Chatterjee  1 , Radha Krishan Dhiman  3 , Martin Hoenigl  4 , Naresh Kumar Tripathy  5
Affiliations
Review

Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: A meta-analysis of 21 studies and 5174 patients

Zia Hashim et al. Mycoses. 2023 Nov.

Abstract

COVID-19-associated pulmonary aspergillosis (CAPA) remains a high mortality mycotic infection throughout the pandemic, and glucocorticoids (GC) may be its root cause. Our aim was to evaluate the effect of systemic GC treatment on the development of CAPA. We systematically searched the PubMed, Google Scholar, Scopus and Embase databases to collect eligible studies published until 31 December 2022. The pooled outcome of CAPA development was calculated as the log odds ratio (LOR) with 95% confidence intervals (CI) using a random effect model. A total of 21 studies with 5174 patients were included. Of these, 20 studies with 4675 patients consisting of 2565 treated with GC but without other immunomodulators (GC group) and 2110 treated without GC or other immunomodulators (controls) were analysed. The pooled LOR of CAPA development was higher for the GC group than for the controls (0.54; 95% CI: 0.22, 0.86; p < .01). In the subgroups, the pooled LOR was higher for high-dose GC (0.90; 95% CI: 0.17, 1.62: p = .01) and dexamethasone (0.71; 95% CI: 0.35, 1.07; p < .01) but had no significant difference for low-dose GC (0.41; 95% CI: -0.07, 0.89; p = .09), and non-dexamethasone GC (0.21; 95% CI: -0.36, 0.79; p = .47), treated patients versus controls. GC treatment increases the risk of CAPA development, and this risk is particularly associated with the use of high-dose GC or dexamethasone treatment.

Keywords: COVID-19-associated pulmonary aspergillosis; glucocorticoids; meta-analysis.

PubMed Disclaimer

References

REFERENCES

    1. WHO Coronavirus (COVID-19) Dashboard, (2022). (Accessed October 10, 2022). https://covid19.who.int.
    1. Borman AM, Fountain H, Guy R, et al. Increased mortality in COVID-19 patients with fungal co- and secondary infections admitted to intensive care or high dependency units in NHS hospitals in England. J Infect. 2022;84:579-613. doi:10.1016/j.jinf.2021.12.047
    1. Hashim Z, Nath A, Khan A, et al. New insights into development and mortality of COVID-19- associated pulmonary aspergillosis in a homogenous cohort of 1161 intensive care patients. Mycoses. 2022;65:1010-1023. doi:10.1111/myc.13485
    1. Fekkar A, Lampros A, Mayaux J, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med. 2021;203:307-317. doi:10.1164/rccm.202009-3400OC
    1. Domán M, Bányai K. COVID-19-associated fungal infections: an urgent need for alternative therapeutic approach? Front Microbiol. 2022;13:919501. doi:10.3389/fmicb.2022.919501

MeSH terms

LinkOut - more resources